Personally, I believe that both Endo pharmaceuticals and Norvatis would already be well aware of Tripeptofen but as you have correctly noted ThermaLIFE's #1 competitor product is the multi-billion dollar Votaren Gel which unfortunately is also of particular concern for people with a high risk of stroke, so in here imo is where the solution to both issues may be happily resolved.
Pharmanet might have something which Novartis/Endo will appreciate to lower the risk of stroke whilst at the same time enhance the performance of their #1 blockbuster...
And in return for making ThermaLIFE's #1 competing product even more competitive perhaps Novartis and Endo can offer something in return which will spare PNO's loyal patient s/holders from ever having to put their hand in their pockets again... or even better still a well earned early retirement ;)
Even when this "Voltaren Gel Samples" is engine searched it coincidentally links to patents which belong to a little known company in Perth?
The following table summarises the field parameters employed in the following studies undertaken with different fields and drugs in in vitro Franz-type diffusion models.
Dermaportation Enhanced Skin Diffusion of a Commercially Available Topical Diclofenac Formulation
Human epidermis was mounted in vertical Franz type diffusion cells (stratum corneum facing up), according to the method of Kligman and Christophers. Voltaren Emulgel® (1g containing 1.16% diclofenac diethylammonium salt; Novartis) was applied to the donor compartment of diffusion cells, with PBS in the receptor compartment (3.0 ml_; stirred continuously; 37 0 C). Dermaportation coils were placed around the exterior of 4 cells, with 4 additional cells without coils (passive control).
Dermaportation energy was applied from time 30-60 min. Samples of the receptor solution were removed and replaced with fresh buffer over an 8 h period. All samples were analysed for diclofenac content by HPLC with UV detection by a validated method. The cumulative amount of diclofenac in receptor versus time was plotted and flux values calculated from the slopes per group. Statistical analyses used a f-test on the delta scores from the zero time point to the time point in question.
Dermaportation enhanced skin penetration of diclofenac (flux 2.97µg/h) compared with passive administration (flux 1.58µg/h). At 8h the cumulative amount penetrated was 14.25µg for Dermaportation and 7.59µg for passive diffusion. The f-test delta score evaluation showed that at 360min and 480min Dermaportation cells had reached a far higher concentration than at the previous time points.
Passive diffusion did not reach diffusion levels different from 0 at any time point. This demonstrates that Dermaportation outperformed passive diffusion
(20min delay)